leisure time -WSS

leisure time

author：knowledge 2025-09-03 03:28:58 - browse：6977

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why hospitals are withdrawing from US News rankings

hotspot

knowledge

WSS

STAT Virtual Event: The State of Biosimilars: What to Watch

Medicare to cover more brain scans for Alzheimer’s patients

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

At Orexo, a ‘turning point’ for everything but digital health

At Orexo, a ‘turning point’ for everything but digital health

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Millions may soon lose Medicaid when they don't have to

Medical leaders decry Supreme Court decision on affirmative action

At Orexo, a ‘turning point’ for everything but digital health

Psychedelics group wrestles with new pharma identity

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Heart attack and stroke risk calculators need revising

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

New air purifier tech could be key to improving indoor air quality

Medicare has a new plan to address drug shortages

focus

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Bispecific antibodies are next new thing in cancer immunotherapy

Timeline: Key moments in fight for gay rights

Altering the blood type of lungs raises potential for universal organs for transplants

AI can’t replace a physician’s gut feeling

FDA approves RSV monoclonal antibody for infants, toddlers

Wikipedia

hotspot

knowledge

entertainment